
Under the Table: Why the U.S. Food and Drug Administration Should Not Approve the Over-the Counter Distribution of Morning After Pills
Published by Population Research Institute Research by Julie Wheeland Executive Summary In May 2004, The U.S. Food and Drug Administraion (FDA) will act on Women’s Capital Corporation/Barr Laboratories application for over-the-counter (OTC) status for so-called “emergency contraception” (EC), the morning-after pill (MAP). Opposition to OTC/MAP